|
US20020160446A1
(en)
*
|
2000-11-14 |
2002-10-31 |
Holtzman Douglas A. |
Novel genes encoding proteins having prognostic diagnostic preventive therapeutic and other uses
|
|
US6313269B1
(en)
*
|
1997-03-14 |
2001-11-06 |
Smithkline Beecham Corporation |
Tumor necrosis factor related receptor, TR6
|
|
US6872568B1
(en)
|
1997-03-17 |
2005-03-29 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5 antibodies
|
|
US20080248046A1
(en)
*
|
1997-03-17 |
2008-10-09 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
|
US20040136951A1
(en)
*
|
1997-03-17 |
2004-07-15 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
|
US20050233958A1
(en)
*
|
1997-03-17 |
2005-10-20 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
|
ES2281126T3
(es)
*
|
1997-03-17 |
2007-09-16 |
Human Genome Sciences, Inc. |
Receptor 5 que contiene un dominio de muerte.
|
|
US6342369B1
(en)
*
|
1997-05-15 |
2002-01-29 |
Genentech, Inc. |
Apo-2-receptor
|
|
ATE516354T1
(de)
*
|
1997-05-15 |
2011-07-15 |
Genentech Inc |
Apo-2-rezeptor
|
|
US20100152426A1
(en)
*
|
1997-05-15 |
2010-06-17 |
Ashkenazi Avi J |
Apo-2 receptor fusion proteins
|
|
JP2001514888A
(ja)
*
|
1997-08-15 |
2001-09-18 |
アイドゥン ファーマシューティカルズ， インコーポレイテッド |
Ｔｒａｉｌレセプター、これをコードする核酸、およびその使用方法
|
|
ES2286856T3
(es)
*
|
1997-09-12 |
2007-12-01 |
Biogen Idec Ma Inc. |
Receptores train ricos en cisteina.
|
|
US6252050B1
(en)
*
|
1998-06-12 |
2001-06-26 |
Genentech, Inc. |
Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
|
|
IL139419A0
(en)
*
|
1998-06-12 |
2001-11-25 |
Genentech Inc |
Monoclonal antibodies, cross-reactive antibodies and method for producing the same
|
|
US20050281821A1
(en)
*
|
1999-01-06 |
2005-12-22 |
Flavia Pernasetti |
Method and composition for angiogenesis inhibition
|
|
US6627199B1
(en)
|
1999-07-09 |
2003-09-30 |
Amgen Inc |
Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family
|
|
US6951738B2
(en)
|
1999-07-16 |
2005-10-04 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptors TR13 and TR14
|
|
AU780060B2
(en)
*
|
1999-07-16 |
2005-02-24 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptors TR13 and TR14
|
|
CA2381284A1
(en)
|
1999-08-04 |
2001-02-15 |
Amgen Inc. |
Fhm, a novel member of the tnf ligand supergene family
|
|
WO2001010908A1
(en)
|
1999-08-04 |
2001-02-15 |
Amgen Inc. |
Ntr3, a member of the tnf-receptor supergene family
|
|
JP2004515203A
(ja)
*
|
1999-08-12 |
2004-05-27 |
ヒューマン ジノーム サイエンシーズ， インコーポレイテッド |
ヒト腫瘍壊死因子レセプターｔｒ１６
|
|
US20030134788A1
(en)
*
|
1999-08-12 |
2003-07-17 |
Baker Kevin P. |
Human tumor necrosis factor receptor TR16
|
|
WO2001023592A2
(en)
*
|
1999-09-27 |
2001-04-05 |
Genentech, Inc. |
Methods for making recombinant proteins using apoptosis inhibitors
|
|
AU2006201322A1
(en)
*
|
1999-09-27 |
2006-04-27 |
Genentech, Inc. |
Methods for making recombinant proteins using apoptosis inhibitors
|
|
IL150755A0
(en)
|
2000-02-16 |
2003-02-12 |
Genentech Inc |
Uses of agonists and antagonists to modulate activity of tnf-related molecules
|
|
MXPA02010011A
(es)
|
2000-04-11 |
2003-04-25 |
Genentech Inc |
Anticuerpos multivalentes y usos para los mismos.
|
|
US7279160B2
(en)
*
|
2000-05-02 |
2007-10-09 |
The Uab Research Foundation |
Combinations of DR5 antibodies and other therapeutic agents
|
|
TWI318983B
(en)
*
|
2000-05-02 |
2010-01-01 |
Uab Research Foundation |
An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
|
|
US7476383B2
(en)
*
|
2000-05-02 |
2009-01-13 |
The Uab Research Foundation |
Antibody selective for DR4 and uses thereof
|
|
KR100436089B1
(ko)
*
|
2000-07-06 |
2004-06-14 |
설대우 |
분비성 재조합 트라이머형의 트레일 단백질 생산을 위한 디엔에이 카세트, 테트라사이클린/독시사이클린-유도성아데노-관련 바이러스 벡터, 이 둘의 조합, 및 이들을이용한 유전자 치료
|
|
US20040005314A1
(en)
*
|
2001-07-27 |
2004-01-08 |
Enrique Escandon |
Apo-2l receptor agonist and cpt-11 synergism
|
|
WO2002009755A2
(en)
|
2000-07-27 |
2002-02-07 |
Genentech, Inc. |
Apo-2l receptor agonist and cpt-11 synergism
|
|
US20060062786A1
(en)
*
|
2000-11-08 |
2006-03-23 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to TRAIL receptors
|
|
US20030228309A1
(en)
*
|
2000-11-08 |
2003-12-11 |
Theodora Salcedo |
Antibodies that immunospecifically bind to TRAIL receptors
|
|
CA2426710A1
(en)
*
|
2000-11-08 |
2002-10-10 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to trail receptors
|
|
US20030139963A1
(en)
*
|
2000-12-08 |
2003-07-24 |
Chickering D. Maxwell |
Decision theoretic approach to targeted solicitation by maximizing expected profit increases
|
|
US20020155109A1
(en)
*
|
2001-04-20 |
2002-10-24 |
Lynch David H. |
Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2
|
|
US7115717B2
(en)
*
|
2001-05-18 |
2006-10-03 |
Kirin Beer Kabushiki Kaisha |
Anti-TRAIL-R antibodies
|
|
US20090226429A1
(en)
*
|
2001-05-25 |
2009-09-10 |
Human Genome Sciences, Inc. |
Antibodies That Immunospecifically Bind to TRAIL Receptors
|
|
US20050214209A1
(en)
*
|
2001-05-25 |
2005-09-29 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to TRAIL receptors
|
|
US7361341B2
(en)
*
|
2001-05-25 |
2008-04-22 |
Human Genome Sciences, Inc. |
Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
|
|
ES2437992T3
(es)
|
2001-05-25 |
2014-01-15 |
Human Genome Sciences, Inc. |
Anticuerpos que se unen inmunoespecíficamente a los receptores de TRAIL
|
|
US20050129616A1
(en)
*
|
2001-05-25 |
2005-06-16 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to TRAIL receptors
|
|
US7348003B2
(en)
|
2001-05-25 |
2008-03-25 |
Human Genome Sciences, Inc. |
Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
|
|
CA2451680C
(en)
|
2001-07-03 |
2011-04-19 |
Genentech, Inc. |
Human dr4 antibodies and uses thereof
|
|
US20030082722A1
(en)
*
|
2001-08-08 |
2003-05-01 |
Bingliang Fang |
Method for amplifying expression from a cell specific promoter
|
|
JP2005508162A
(ja)
|
2001-10-02 |
2005-03-31 |
ジェネンテック・インコーポレーテッド |
Ａｐｏ−２リガンド変異体とその使用法
|
|
IL161812A0
(en)
|
2001-11-13 |
2005-11-20 |
Genentech Inc |
Apo2 ligand/trail formulations
|
|
US7741285B2
(en)
|
2001-11-13 |
2010-06-22 |
Genentech, Inc. |
APO-2 ligand/trail formulations
|
|
US7842668B1
(en)
|
2001-11-13 |
2010-11-30 |
Genentech, Inc. |
Apo-2 ligand/trail formulations
|
|
CA2471140A1
(en)
*
|
2001-12-20 |
2003-07-03 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to trail receptors
|
|
EP1556076A4
(en)
|
2002-06-24 |
2009-07-08 |
Genentech Inc |
APO-2 LIGAND / TRAIL VARIANTS AND ITS USES
|
|
PT1606318E
(pt)
*
|
2003-03-26 |
2009-11-10 |
Deutsches Krebsforsch |
Proteínas de fusão de fc melhoradas
|
|
WO2005092927A1
(en)
|
2004-03-23 |
2005-10-06 |
Biogen Idec Ma Inc. |
Receptor coupling agents and therapeutic uses thereof
|
|
AU2005271601A1
(en)
|
2004-08-06 |
2006-02-16 |
Genentech, Inc. |
Assays and methods using biomarkers
|
|
MX2007001468A
(es)
*
|
2004-08-06 |
2007-03-26 |
Genentech Inc |
Ensayos y metodos que utilizan biomarcadores.
|
|
BRPI0515615A
(pt)
*
|
2004-09-08 |
2008-07-29 |
Genentech Inc |
métodos para tratar células cancerosas e doença imune relacionada
|
|
EP1802660A2
(en)
*
|
2004-09-08 |
2007-07-04 |
Genentech, Inc. |
Methods of using death receptor ligands and cd20 antibodies
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
US8029783B2
(en)
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
|
BRPI0606791A2
(pt)
*
|
2005-02-02 |
2010-02-09 |
Uab Research Foundation |
métodos de reverter ou prevenir a resistência de uma célula a um agonista do receptor da morte, de triar uma célula quanto a um biomarcador da resistência a um agonista do receptor da morte, de monitorar a resistência a um agonista do receptor da morte em um indivìduo, de induzir seletivamente a apoptose em uma célula alvo expressando um receptor da morte, de tratar de um indivìduo com cáncer, de tratar de um indivìduo com uma doença inflamatória ou autoimune, de bloquear a ligação da proteìna contendo card a um receptor da morte em uma célula, de bloquear a associação de um iap com o receptor da morte e de triar um modulador de uma proteìna contendo card, composição, ácido nucleico isolado, vetor, célula, e, polipeptìdeo isolado
|
|
US20090155247A1
(en)
*
|
2005-02-18 |
2009-06-18 |
Ashkenazi Avi J |
Methods of Using Death Receptor Agonists and EGFR Inhibitors
|
|
US20060188498A1
(en)
*
|
2005-02-18 |
2006-08-24 |
Genentech, Inc. |
Methods of using death receptor agonists and EGFR inhibitors
|
|
US7629315B2
(en)
*
|
2005-03-09 |
2009-12-08 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Compositions for blocking the inhibitory effect of human CRP on human leptin
|
|
PT1915626E
(pt)
|
2005-08-16 |
2012-02-03 |
Genentech Inc |
Sensibilidade da apoptose a apo2l/trail por ensaio de expressão de galnac-t14 em células/tecidos
|
|
CA2619654A1
(en)
*
|
2005-08-24 |
2007-03-01 |
Cell Matrix |
Combination therapies for inhibiting integrin-extracellular matrix interactions
|
|
AU2006318539B2
(en)
|
2005-11-23 |
2012-09-13 |
Genentech, Inc. |
Methods and compositions related to B cell assays
|
|
US8957187B2
(en)
|
2005-12-02 |
2015-02-17 |
Genentech, Inc. |
Binding polypeptides and uses thereof
|
|
US20070218504A1
(en)
*
|
2006-03-09 |
2007-09-20 |
University Of Pittsburgh |
Human leptin-derived polypeptides and uses thereof
|
|
JP2012504969A
(ja)
|
2008-10-10 |
2012-03-01 |
アナフォア インコーポレイテッド |
Ｔｒａｉｌ−ｒ１及びｔｒａｉｌ−ｒ２に結合するポリペプチド
|
|
WO2011043835A1
(en)
*
|
2009-10-09 |
2011-04-14 |
Anaphore, Inc. |
Polypeptides that bind il-23r
|
|
KR20120101050A
(ko)
|
2009-11-05 |
2012-09-12 |
더 유에이비 리서치 파운데이션 |
기저형 유전자형 암의 치료 방법
|
|
US8703712B2
(en)
|
2010-03-18 |
2014-04-22 |
The Uab Research Foundation |
Targeting cancer stem cells with DR5 agonists
|
|
RU2644678C1
(ru)
|
2010-10-29 |
2018-02-13 |
Дайити Санкио Компани, Лимитед |
Новое антитело против dr5
|
|
WO2012117336A2
(en)
|
2011-02-28 |
2012-09-07 |
Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Burlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale Per La Salute Della Donna E Del Bambino |
Apoptosis-inducing molecules and uses therefor
|
|
CA2834776A1
(en)
|
2011-05-03 |
2012-11-08 |
Genentech, Inc. |
Therapeutic apo2l/trail polypeptides and death receptor agonist antibodies
|
|
CN102898526A
(zh)
*
|
2011-07-28 |
2013-01-30 |
山东先声麦得津生物制药有限公司 |
一种肿瘤坏死因子相关凋亡诱导配体融合蛋白及其制备和应用
|
|
WO2014159562A1
(en)
|
2013-03-14 |
2014-10-02 |
Bristol-Myers Squibb Company |
Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
|
|
GB201312155D0
(en)
*
|
2013-07-05 |
2013-08-21 |
Ucl Business Plc |
Therapeutic invention
|
|
WO2015138638A1
(en)
|
2014-03-11 |
2015-09-17 |
Theraly Pharmaceuticals, Inc. |
Long acting trail receptor agonists for treatment of autoimmune diseases
|
|
US11007251B2
(en)
|
2015-12-17 |
2021-05-18 |
The Johns Hopkins University |
Ameliorating systemic sclerosis with death receptor agonists
|
|
CN109195620B
(zh)
|
2016-04-07 |
2022-06-28 |
约翰霍普金斯大学 |
用死亡受体激动剂治疗胰腺炎和疼痛的组合物和方法
|
|
EP3323428A1
(en)
|
2016-11-17 |
2018-05-23 |
CNRS Centre National de la Recherche Scientifique |
Selective c-flip inhibitors as anticancer agents
|
|
EP3910331A1
(en)
|
2020-05-15 |
2021-11-17 |
iOmx Therapeutics AG |
Intracellular kinase associated with resistance against t-cell mediated cytotoxicity, and uses thereof
|
|
GB202016058D0
(en)
|
2020-10-09 |
2020-11-25 |
Ucl Business Ltd |
Therapeautic treatment
|
|
EP4257132A1
(en)
|
2022-04-08 |
2023-10-11 |
iOmx Therapeutics AG |
Sik3 inhibitors for treating diseases resistant to death receptor signalling
|
|
WO2024175554A1
(en)
|
2023-02-21 |
2024-08-29 |
Institut Curie |
Trail agonists for use in the treatment of cancer in patients having an activating alteration of fgfr3
|